Bicalutamide (Casodex®®) in the treatment of prostate cancer. Issue 1 (1st February 2004)

• Record Type: Journal Article
• Authors: Fradet, Yves
• Is Part Of: Expert review of anticancer therapy. Volume 4:Issue 1(2004)
• Page Start: 37
• Page End: 48
• Publication Date: 2004-02-01
• Subjects: bicalutamide -- efficacy -- nonsteroidal antiandrogen -- prostate cancer -- quality of life -- sexual interest -- tolerability; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.4.1.37
• Languages: English
• ISSNs: 1473-7140

Abstract

Prostate cancer is an important healthcare issue in men worldwide. With the advent of prostate-specific antigen screening and improved diagnostic techniques, prostate cancer is now being diagnosed in younger men and at earlier disease stages. As a result, patients often live with their disease for many years after diagnosis. This shift in the patient profile has focused attention to the impact of treatment on quality of life. Medical/surgical castration has traditionally been the mainstay of hormonal therapy but is associated with side effects including loss of libido and impotence. Nonsteroidal antiandrogens such as bicalutamide (Casodex ®® ) offer an effective alternative to castration with potential quality-of-life benefits. This paper reviews the evidence concerning the use of bicalutamide at all stages of the disease.